Adthera Bio

Adthera Bio is a private, UK-based CDMO founded in 2018, operating in the high-growth cell and gene therapy sector. Its business model is service-oriented, providing process development, manufacturing science, and regulatory support to therapy developers, positioning it as a critical enabler in the ATMP supply chain. The company is likely in an early-revenue stage, leveraging a 'digital-first' approach to differentiate itself through automation and data-driven processes. Its success is tied to the overall expansion of the cell and gene therapy market and its ability to secure partnerships with emerging biotechs.

Digital-first CDMO platform integrating process automation, data analytics, and advanced process control for cell and gene therapy manufacturing.

Adthera Bio competes in the specialized CGT CDMO space against large, diversified players like Lonza, Catalent, and Thermo Fisher Scientific, as well as pure-play competitors like Oxford Biomedica, Charles River's Cognate BioServices, and ElevateBio. Its differentiation hinges on a targeted, technology-enabled service model for a complex product class.